`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF MINNESOTA
`MINNEAPOLIS DIVISION
`
`
`MARIA MALO,
`
`
`PLAINTIFF,
`
`
`VS.
`
`
`TORAX MEDICAL, INC., AND
`ETHICON, INC.
`
`DEFENDANTS.
`
`
`
`
`
`
`
`CIVIL ACTION NO. _ 0:21-cv-2123__
`
`§
`§
`§
`§
`§
`§ JURY DEMANDED
`§
`§
`§
`§
`
`
`
`
`
`
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`Plaintiff Maria Malo files this, her Original Complaint, against Defendants Torax Medical,
`
`Inc. and Ethicon Inc., and respectfully states follows:
`
`I.
`
`PRELIMINARY STATEMENT
`
`Defendant’s Torax Medical, Inc. and Ethicon, Inc. manufactured a defective medical
`
`device such that Plaintiff suffered significant injury. Here, a defectively manufactured LINX was
`
`surgically implanted in Plaintiff to control her gastroesophageal reflux disease (GERD). After the
`
`LINX was implanted in Plaintiff, Defendants became aware of the manufacturing defect in
`
`Plaintiff’s LINX. Defendants recalled Plaintiff’s LINX as well as numerous other LINX devices
`
`in the United States and European Union. Moreover, Defendants admit that Plaintiff’s LINX was
`
`defectively manufactured.
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 1 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 2 of 16
`
`Here, Plaintiff seeks to vindicate her rights at law for having to experience a severe
`
`recurrence of her GERD symptoms and undergo another invasive surgery to remove the defective
`
`LINX.
`
`
`
`1.
`
`2.
`
`II.
`
`PARTIES
`
`Plaintiff Maria Malo is a resident of the State of Texas.
`
`Defendant Torax Medical, Inc. (Torax) is a Delaware corporation with its
`
`headquarters and principal place of business in Shoreview, Minnesota. Torax may be served with
`
`process through its registered agent, The Corporation Trust Company at 1209 Orange St.,
`
`Wilmington, Delaware 19801, or wherever it may be found. While headquartered in Minnesota,
`
`Torax’s medical devices, including the LINX, are distributed, marketed, sold, and used on medical
`
`patients in all fifty United States, including Minnesota, and the European Union. Therefore, Torax
`
`is subject to personal jurisdiction in the State of Minnesota.
`
`3.
`
`Ethicon, Inc. (Ethicon) is a New Jersey corporation with its headquarters and
`
`principal place of business in the State of New Jersey. Ethicon may be served with process through
`
`its registered agent Johnson & Johnson, at One Johnson & Johnson Plaza, New Brunswick, New
`
`Jersey 08933-0000, or its president Nefertiti Green, at Johnson & Johnson, Rt. 22 West,
`
`Somerville, New Jersey 08876, or wherever she may be found. While headquartered in New
`
`Jersey, Ethicon’s medical devices, including the LINX, are distributed, marketed, sold, and used
`
`on medical patients in all fifty United States, including Minnesota, and the European Union.
`
`Therefore, Ethicon is subject to personal jurisdiction in the State of Minnesota.
`
`
`
`
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 2 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 3 of 16
`
`III.
`
`JURISDICTION & VENUE
`
`4.
`
`This Court has jurisdiction over this proceeding pursuant to 28 U.S.C. § 1332(a)(1).
`
`The amount in controversy exceeds $75,000.00.
`
`5.
`
`Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391(b)(1) and (2).
`
`IV.
`
`FACTS APPLICABLE TO ALL COUNTS
`
`6.
`
`This case arises from the defective manufacturing by Defendants Torax and Ethicon
`
`of a medical device known as the “LINX Reflux Management System” (“LINX”). LINX is a
`
`titanium bead-and-wire ring surgically implanted around a patient’s lower esophageal sphincter
`
`(LES) to augment the LES and prevent acid reflux. These devices can only be implanted surgically,
`
`and they are used to treat gastroesophageal reflux disease (GERD) which is a disease
`
`predominately suffered by the elderly.
`
`1
`
`
`1 https://www.jnj.com/innovation/johnson-johnson-medical-innovations-reshaping-future-surgery
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 3 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 4 of 16
`
`7.
`
`The LINX required pre-market approval by the Food & Drug Administration prior
`
`to it being placed in the stream of commerce and used on patients in the United States and the
`
`European Union. Specifically, in December 2010, Defendant Torax applied for this pre-market
`
`approval, including its manufacturing process, and this approval was granted on March 22, 2012.
`
`The LINX is considered a “restricted” device, meaning it is subject to numerous FDA regulations
`
`regarding the manufacture, distribution, and marketing of the device.
`
`8.
`
`Defendant Ethicon, Inc. (Ethicon) is the parent-corporation for Defendant Torax
`
`and participated in the manufacture, distribution, and post-market surveillance of the LINX.
`
`9.
`
`On May 31, 2018, Defendant Torax initiated a recall of numerous LINX due to “an
`
`out of specification condition” which would allow “a bead component to separate from an adjacent
`
`wire link.”2 This means that the LINX device, normally a continuous loop, would become
`
`discontinuous and open due a defect resulting from improper manufacture.
`
`
`
`
`
`This recall, classified as a Class 2 recall, is considered by the FDA as “a method of
`
`removing…products that are in violation of laws” administered by the FDA. FDA records show
`
`that there were 9,131 LINX devices in the stream of commerce as of May 2018.
`
`
`2 See Exhibit “A” – Notice of Recall
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 4 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 5 of 16
`
`10.
`
`A 17-bead LINX was surgically implanted in Plaintiff on June 1, 2018. This LINX
`
`was subject to the recall described in ¶ 6.
`
`11.
`
`12.
`
`Plaintiff the defective LINX was removed on December 2, 2020.
`
`Plaintiff alleges that Defendants Torax and Ethicon manufactured the LINX which
`
`was implanted in Plaintiff and subsequently failed due to a manufacturing defect. Plaintiff alleges
`
`that Defendants Torax and Ethicon placed Plaintiff’s LINX device into the stream of commerce.
`
`Plaintiff alleges that Defendants Torax and Ethicon are corporations who regularly design, test,
`
`assembly, manufacture, sell, and distribute medical devices intended for human use.
`
`
`V.
`
`CAUSES OF ACTION
`
`A. Manufacturing Defect As to Defendant Torax – Strict Liability
`
`13.
`
`Plaintiff incorporates the above paragraphs and would show the Court that she is
`
`entitled to recover from, in strict liability for product defect, from Defendant Torax for the
`
`defective manufacture of the LINX device surgically-implanted in Plaintiff.
`
`14.
`
`Specifically, the LINX implanted in Plaintiff was manufactured in violation of the
`
`Federal Food, Drug, and Cosmetic Act, the Medical Device Amendments, and federal regulations
`
`promulgated under these laws and administered by the FDA. The device implanted in Plaintiff was
`
`manufactured in deviation from the manufacturing specifications approved by the FDA and
`
`provided by Defendant Torax for its pre-market approval. Plaintiff’s LINX was also manufactured
`
`in deviation of Current Good Manufacturing Practice requirements. The LINX was also
`
`defectively manufactured in violation of Minnesota law that parallels federal requirements.
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 5 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 6 of 16
`
`15.
`
`Specifically, Defendant Torax was required to manufacture the defective LINX
`
`device according to Federal Regulations, including but not limited to the following, and failed to
`
`do so in:
`
` 21 CFR 820.5 – failure to establish and adhere to a quality system to prevent the
`
`manufacture of defective LINX;
`
` 21 CFR 820.20 – failure to adhere to approved quality system procedures;
`
` 21 CFR 820.70(a),(g), (h), (i) – failure to control production processes to ensure device
`
`conformance with specifications;
`
` 21 CFR 820.72 – failure to inspect, measure, and test manufacturing equipment and
`
`materials such that the LINX was defectively manufactured;
`
` 21 CFR 820.75 – failure to adhere to process validation and implement process
`
`validation such that the LINX was placed in the stream of commerce in a defective
`
`condition;
`
` 21 CFR 820.90 – failure to prevent non-conforming product, e.g. Plaintiff’s LINX,
`
`from entering the stream of commerce in a defective condition;
`
` 21 CFR 820.100 – failure to implement corrective processes and preventative actions
`
`due to nonconformities.
`
`16.
`
`As a result of Defendant Torax’s violations of federal regulation, approved-
`
`manufacturing process, and manufacturing standard of care, Plaintiff’s LINX was defectively
`
`manufactured and failed as a result of that defect. At the time the LINX device left the control of
`
`Defendant Torax, it was outside of manufacturing specification and was unreasonably dangerous
`
`due to its defective manufacture.
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 6 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 7 of 16
`
`17.
`
`Each of the foregoing violations, whether taken singularly or in any combination,
`
`were a proximate cause of Plaintiff’s injuries and damages which are described in more detail
`
`above and below. Plaintiff seeks compensatory damages, jointly and severally.
`
`B. Manufacturing Defect As to Defendant Torax – Negligence
`
`18.
`
`Plaintiff incorporates the above paragraphs and would show the Court that she is
`
`entitled to recover from Defendant Torax for the defective manufacture of the LINX device
`
`surgically-implanted in Plaintiff.
`
`19.
`
`Specifically, Defendant Torax owed Plaintiff a duty of ordinary care as would a
`
`reasonable and prudent manufacturer of medical devices to manufacture the LINX such that it
`
`would be safe for its intended use. Plaintiff alleges that Defendant Torax failed to use ordinary
`
`care by various acts and omissions, which constitute negligence, in at least the following ways:
`
` Failure to manufacture the LINX consistent with approved manufacturing standards
`
`such that it was defective and unreasonably dangerous for its intended use;
`
` Failure to manufacture the LINX consistent with approved design such that it was
`
`defective and unreasonably dangerous for its intended use;
`
` Failure to test and inspect the device prior to placing it in the stream of commerce in a
`
`defective and unreasonably dangerous condition; and
`
` Failure to prevent the defectively manufactured device from entering the stream of
`
`commerce in a defective and unreasonably dangerous condition.
`
`20.
`
`As a result of Defendant Torax’s breach of its duty of care, Plaintiff’s LINX was
`
`defectively manufactured and failed as a result of that defect. At the time the LINX device left the
`
`control of Defendant Torax, it was outside of manufacturing specification and was unreasonably
`
`dangerous due to its defective manufacture.
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 7 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 8 of 16
`
`21.
`
`Each of the foregoing violations, whether taken singularly or in any combination,
`
`were a proximate cause of Plaintiff’s injuries and damages which are described in more detail
`
`above and below. Plaintiff seeks compensatory damages, jointly and severally.
`
`C. Manufacturing Defect As to Defendant Torax – Negligence Per Se
`
`22.
`
`Plaintiff incorporates the above paragraphs and would show the Court that she is
`
`entitled to recover from, in negligence per se, from Defendant Torax for the defective manufacture
`
`of the LINX device surgically-implanted in Plaintiff.
`
`23.
`
`Specifically, the LINX implanted in Plaintiff was manufactured in violation of the
`
`Federal Food, Drug, and Cosmetic Act, the Medical Device Amendments, and federal regulations
`
`promulgated under these laws and administered by the FDA. The device implanted in Plaintiff was
`
`manufactured in deviation from the manufacturing specifications approved by the FDA and
`
`provided by Defendant Torax for its pre-market approval. Plaintiff’s LINX was also manufactured
`
`in deviation of Current Good Manufacturing Practice requirements. The LINX was also
`
`defectively manufactured in violation of Minnesota law that parallels federal requirements.
`
`24.
`
`Specifically, Defendant Torax was required to manufacture the defective LINX
`
`device according to Federal Regulations, including but not limited to the following, and failed to
`
`do so in:
`
` 21 CFR 820.5 – failure to establish and adhere to a quality system to prevent the
`
`manufacture of defective LINX;
`
` 21 CFR 820.20 – failure to adhere to approved quality system procedures;
`
` 21 CFR 820.70(a),(g), (h), (i) – failure to control production processes to ensure device
`
`conformance with specifications;
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 8 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 9 of 16
`
` 21 CFR 820.72 – failure to inspect, measure, and test manufacturing equipment and
`
`materials such that the LINX was defectively manufactured;
`
` 21 CFR 820.75 – failure to adhere to process validation and implement process
`
`validation such that the LINX was placed in the stream of commerce in a defective
`
`condition;
`
` 21 CFR 820.90 – failure to prevent non-conforming product, e.g. Plaintiff’s LINX,
`
`from entering the stream of commerce in a defective condition;
`
` 21 CFR 820.100 – failure to implement corrective processes and preventative actions
`
`due to nonconformities.
`
`25.
`
`26.
`
`These violations constitute negligence per se.
`
`As a result of Defendant Torax’s violations of federal regulation, approved-
`
`manufacturing process, and manufacturing standard of care, Plaintiff’s LINX was defectively
`
`manufactured and failed as a result of that defect. At the time the LINX device left the control of
`
`Defendant Torax, it was outside of manufacturing specification and was unreasonably dangerous
`
`due to its defective manufacture.
`
`27.
`
`Each of the foregoing violations, whether taken singularly or in any combination,
`
`were a proximate cause of Plaintiff’s injuries and damages which are described in more detail
`
`above and below. Plaintiff seeks compensatory damages, jointly and severally.
`
`D. Manufacturing Defect As to Defendant Ethicon – Strict Liability
`
`28.
`
`Plaintiff incorporates the above paragraphs and would show the Court that she is
`
`entitled to recover from, in strict liability for product defect, from Defendant Ethicon for the
`
`defective manufacture of the LINX device surgically-implanted in Plaintiff.
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 9 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 10 of 16
`
`29.
`
`Specifically, the LINX implanted in Plaintiff was manufactured in violation of the
`
`Federal Food, Drug, and Cosmetic Act, the Medical Device Amendments, and federal regulations
`
`promulgated under these laws and administered by the FDA. The device implanted in Plaintiff was
`
`manufactured in deviation from the manufacturing specifications approved by the FDA. Plaintiff’s
`
`LINX was also manufactured in deviation of Current Good Manufacturing Practice requirements.
`
`The LINX was also defectively manufactured in violation of Minnesota law that parallels federal
`
`requirements.
`
`30.
`
`Specifically, Defendant Ethicon was required to manufacture the defective LINX
`
`device according to Federal Regulations, including but not limited to the following, and failed to
`
`do so in:
`
` 21 CFR 820.5 – failure to establish and adhere to a quality system to prevent the
`
`manufacture of defective LINX;
`
` 21 CFR 820.20 – failure to adhere to approved quality system procedures;
`
` 21 CFR 820.70(a),(g), (h), (i) – failure to control production processes to ensure device
`
`conformance with specifications;
`
` 21 CFR 820.72 – failure to inspect, measure, and test manufacturing equipment and
`
`materials such that the LINX was defectively manufactured;
`
` 21 CFR 820.75 – failure to adhere to process validation and implement process
`
`validation such that the LINX was placed in the stream of commerce in a defective
`
`condition;
`
` 21 CFR 820.90 – failure to prevent non-conforming product, e.g. Plaintiff’s LINX,
`
`from entering the stream of commerce in a defective condition;
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 10 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 11 of 16
`
` 21 CFR 820.100 – failure to implement corrective processes and preventative actions
`
`due to nonconformities.
`
`31.
`
`As a result of Defendant Ethicon’s violations of federal regulation, approved-
`
`manufacturing process, and manufacturing standard of care, Plaintiff’s LINX was defectively
`
`manufactured and failed as a result of that defect. At the time the LINX device left the control of
`
`Defendant Ethicon, it was outside of manufacturing specification and was unreasonably dangerous
`
`due to its defective manufacture.
`
`32.
`
`Each of the foregoing violations, whether taken singularly or in any combination,
`
`were a proximate cause of Plaintiff’s injuries and damages which are described in more detail
`
`above and below. Plaintiff seeks compensatory damages, jointly and severally.
`
`E. Manufacturing Defect As to Defendant Ethicon – Negligence
`
`33.
`
`Plaintiff incorporates the above paragraphs and would show the Court that she is
`
`entitled to recover from Defendant Ethicon for the defective manufacture of the LINX device
`
`surgically-implanted in Plaintiff.
`
`34.
`
`Specifically, Defendant Ethicon owed Plaintiff a duty of ordinary care as would a
`
`reasonable and prudent manufacturer of medical devices to manufacture the LINX such that it
`
`would be safe for its intended use. Plaintiff alleges that Defendant Ethicon failed to use ordinary
`
`care by various acts and omissions, which constitute negligence, in at least the following ways:
`
` Failure to manufacture the LINX consistent with approved manufacturing standards
`
`such that it was defective and unreasonably dangerous for its intended use;
`
` Failure to manufacture the LINX consistent with approved design such that it was
`
`defective and unreasonably dangerous for its intended use;
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 11 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 12 of 16
`
` Failure to test and inspect the device prior to placing it in the stream of commerce in a
`
`defective and unreasonably dangerous condition; and
`
` Failure to prevent the defectively manufactured device from entering the stream of
`
`commerce in a defective and unreasonably dangerous condition.
`
`35.
`
`As a result of Defendant Ethicon’s breach of its duty of care, Plaintiff’s LINX was
`
`defectively manufactured and failed as a result of that defect. At the time the LINX device left the
`
`control of Defendant Ethicon, it was outside of manufacturing specification and was unreasonably
`
`dangerous due to its defective manufacture.
`
`36.
`
`Each of the foregoing violations, whether taken singularly or in any combination,
`
`were a proximate cause of Plaintiff’s injuries and damages which are described in more detail
`
`above and below. Plaintiff seeks compensatory damages, jointly and severally.
`
`F.
`
`37.
`
`Manufacturing Defect As to Defendant Ethicon – Negligence Per Se
`
`Plaintiff incorporates the above paragraphs and would show the Court that she is
`
`entitled to recover from, in negligence per se, from Defendant Ethicon for the defective
`
`manufacture of the LINX device surgically-implanted in Plaintiff.
`
`38.
`
`Specifically, the LINX implanted in Plaintiff was manufactured in violation of the
`
`Federal Food, Drug, and Cosmetic Act, the Medical Device Amendments, and federal regulations
`
`promulgated under these laws and administered by the FDA. The device implanted in Plaintiff was
`
`manufactured in deviation from the manufacturing specifications approved by the FDA. Plaintiff’s
`
`LINX was also manufactured in deviation of Current Good Manufacturing Practice requirements.
`
`The LINX was also defectively manufactured in violation of Minnesota law that parallels federal
`
`requirements.
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 12 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 13 of 16
`
`39.
`
`Specifically, Defendant Ethicon was required to manufacture the defective LINX
`
`device according to Federal Regulations, including but not limited to the following, and failed to
`
`do so in:
`
` 21 CFR 820.5 – failure to establish and adhere to a quality system to prevent the
`
`manufacture of defective LINX;
`
` 21 CFR 820.20 – failure to adhere to approved quality system procedures;
`
` 21 CFR 820.70(a),(g), (h), (i) – failure to control production processes to ensure device
`
`conformance with specifications;
`
` 21 CFR 820.72 – failure to inspect, measure, and test manufacturing equipment and
`
`materials such that the LINX was defectively manufactured;
`
` 21 CFR 820.75 – failure to adhere to process validation and implement process
`
`validation such that the LINX was placed in the stream of commerce in a defective
`
`condition;
`
` 21 CFR 820.90 – failure to prevent non-conforming product, e.g. Plaintiff’s LINX,
`
`from entering the stream of commerce in a defective condition;
`
` 21 CFR 820.100 – failure to implement corrective processes and preventative actions
`
`due to nonconformities.
`
`40.
`
`41.
`
`These violations constitute negligence per se.
`
`As a result of Defendant Ethicon’s violations of federal regulation, approved-
`
`manufacturing process, and manufacturing standard of care, Plaintiff’s LINX was defectively
`
`manufactured and failed as a result of that defect. At the time the LINX device left the control of
`
`Defendant Ethicon, it was outside of manufacturing specification and was unreasonably dangerous
`
`due to its defective manufacture.
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 13 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 14 of 16
`
`42.
`
`Each of the foregoing violations, whether taken singularly or in any combination,
`
`were a proximate cause of Plaintiff’s injuries and damages which are described in more detail
`
`above and below. Plaintiff seeks compensatory damages, jointly and severally.
`
`VI.
`
`DAMAGES
`
`
`
`43.
`
`Plaintiff suffered, as a proximate and direct result of the wrongful actions and/or
`
`omissions of the Defendants in this matter, each of the following damages:
`
`A.
`
`Reasonable medical care and expenses in the past. These expenses were incurred
`
`by the Plaintiff for the necessary care and treatment of the injuries resulting from
`
`the manufacturing defect alleged and such charges are reasonable and were usual
`
`and customary charges for such services;
`
`B.
`
`Reasonable and necessary medical care and expenses which will in all reasonable
`
`probability be incurred in the future;
`
`Physical pain and suffering in the past;
`
`Physical pain and suffering which will in all reasonable probability be suffered in
`
`the future;
`
`Mental anguish sustained in the past;
`
`Mental anguish that, in reasonable probability, Plaintiff will sustain in the future;
`
`Physical impairment in the past;
`
`Physical impairment which, in all reasonable probability, will be suffered in the
`
`future;
`
`Disfigurement; and
`
`Costs of Court.
`
`C.
`
`D.
`
`E.
`
`F.
`
`G.
`
`H.
`
`I.
`
`J.
`
`
`
`
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 14 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 15 of 16
`
`VI.
`
`REQUEST FOR JURY TRIAL
`
`Pursuant to Federal Rule of Civil Procedure 38, Plaintiff makes his demand for trial by jury
`
`on all issues so triable.
`
`VII.
`
`PRAYER
`
`Plaintiff request that the Court award her the following relief against the Defendants above
`
`as may be appropriate:
`
`(1)
`
`(2)
`
`(3)
`
`A Judgment awarding actual, compensatory, damages in the amount in excess of
`75,000.00;
`
`Costs of court;
`
`Pre- and post-judgment interest at the highest legal rate allowed by law from the
`earliest time allowed by law; and
`
`(4)
`
`All other relief to which Plaintiff is justly entitled.
`
`
`Dated: September 27, 2021
`
`Respectfully submitted,
`
`MESHBESHER & SPENCE
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`__/s/ Ashleigh Raso_____________
`ASHLEIGH RASO
`State Bar Minnesota No. 0393353
`1616 Park Avenue
`Minneapolis, Minnesota 55404
`Telephone:
`(612) 339-9121
`E-Mail: araso@meshbesher.com
`
`
`
`
`
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 15 OF 16
`
`
`
`CASE 0:21-cv-02123-ECT-BRT Doc. 1 Filed 09/27/21 Page 16 of 16
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`SAWICKI LAW
`
`
`MICHAEL G. SAWICKI
`Texas State Bar No. 17692500
`ANDREW A. JONES
`Texas State Bar No. 24077910
`6116 N. Central Expressway, Ste. 1400
`Dallas, Texas 75206
`Telephone:
`(214) 468-8844
`Fax:
`
`(214) 468-8845
`E-Mail: msawicki@sawickilawfirm.com
`E-Mail: ajones@sawickilawfirm.com
`
`ATTORNEYS FOR PLAINTIFF
`Pro Hac Vice Motions Pending
`
`
`
`
`
`
`
`
`
`
`
`
`
`PLAINTIFF’S ORIGINAL COMPLAINT
`
`PAGE 16 OF 16
`
`